Beyond discrimination, the observed interplay between CSF tau dynamics and immunoglobulin profiles and clinical features generates testable hypotheses linking blood–brain barrier dysfunction and immune activation to ALS/FTD pathophysiology. This evidence concerns the gene MAPT and amyotrophic lateral sclerosis.